Discover PANGAEA’s world

Our PhDs participate in scientific publications in peer-reviewed journals

Our latest news, events, meetings, announcements and stories

OUR LATEST SCIENTIFIC PUBLICATIONS

“Promising outlook with sugemalimab in non-small-cell lung cancer” Lancet Oncology 2022 Published Online January 14, (Vol 23): 186-187, 2022. IF: 41.316.
“Ablating lung cancer, knowing the tumor better” The Lancet Regional Health – Europe 2022;22: 100494.
“Classification of atypical EGFR mutations in non-small-cell lung cancer” Ann Oncol 2022 Mar 21;S0923-7534(22)00389-1. Vol 33, Issue 6, P571-573, June 01, 2022 IF: 51.769.
“Location of EGFR exon 20 insertions matters” Cancer Cell 2022. IF: 31.743.

“COVID-19 in Melanoma Patients: Results of the Spanish Melanoma Group Registry, GRAVID study” Journal of the American Academy of Dermatology 2021, 84 (5): 1412-1415. IF: 8.277.
“Poziotinib treatment in intractable NSCLC: EGFR and HER2 exon 20 insertion mutation disease” European Journal of Cancer, 2021. IF: 7.275.
“Cemiplimab monotherapy in advanced non-squamous and squamous NSCLC” Lancet 2021. Vol 397 February 13: 557-559. IF: 60.392.
“Analysis of extracellular vesicle mRNA derived from plasma using the nCounter platform” Sci Rep 11, 3712 (2021). IF: 3.99.

“Neoadjuvant atezolizumab plus chemotherapy in resectable non-small-cell lung cancer” Lancet Oncology, 2020 Jun;21(6):736-738. IF: 35. 386.
“Poziotinib treatment in intractable NSCLC: EGFR and HER2 exon 20 insertion mutation disease” European Journal of Cancer, 2021. IF: 7.275.
“Safety of anti-PD-L1 inhibition in HIV-1-infected cancer patients” (Response letter of A. Dekker). JAMA Oncology 2020. (Accepted). IF: 22.416.
“Targeting MET amplification in EGFR-mutant non-small-cell lung cancer” Lancet Respir Med. 2020 Published online May 22, 2020. IF: 15.780.

“Profile of alectinib for the treatment of ALK-positive Non-Small Cell Lung Cancer (NSCLC): patient selection and perspectives” OncoTargets and Therapy 2019. IF: 2.656.
“EGFR first- and second-generation TKIs—there is still place for them in EGFR-mutant NSCLC patients” Transl Cancer Res 2019; 8 (Suppl 1): S23-S47 IF: 1.2.
“PIM-1 inhibition with AZD1208 to prevent osimertinibinduced resistance in EGFR-mutation positive non-small cell lung cancer.” Journal of Cancer Metastasis and Treatment 2019.
“Human Papillomavirus Infection and Lung Cancer Current Perspectives in Human Papillomavirus” (BOOK CHAPTER) IntechOpen, 2019.

“Unsuspected N2-positive non-small cell lung cancer after complete resection: is there a place for multimodal adjuvant therapy?” AME Medical Journal. February 2018.
“Common Co-activation of AXL and CDCP1 in EGFR-mutation-positive Non-small cell Lung Cancer Associated With Poor Prognosis” EBioMedicine, February 2018, Epub ahead of print.
“Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients” AME Medical Journal. Therapeutic Advances in Medical Oncology, January 18, 2018.
“Combination of immunotherapy with targeted therapies in advanced non-small cell lung cancer (NSCLC)” Therapeutic Advances in Medical Oncology, January 9, 2018.

Discover our latest news

  • All Post
  • Instituto Oncológico Rosell
  • International Breast Cancer Center
  • Pangaea Oncology
  • Quénet Torrent Institute